Glenmark Pharmaceuticals Recalls Chlorpromazine HCl Tablets Over Nitrosamine Impurity: Critical Supply Chain Implications
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall (D-0159-2025) for Chlorpromazine Hydrochloride Tablets due to N-Nitroso-Desmethyl Chlorpromazine impurity exceeding FDA limits. This CGMP deviation highlights critical quality control challenges, impacting supply chain stability and regulatory compliance for procurement directors. Companies must reassess supplier qualification and impurity testing protocols for active pharmaceutical ingredients, especially those manufactured offshore.
FDA Mandates Class II Recall for Glenmark's Chlorpromazine Hydrochloride Due to Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ, has initiated a voluntary, firm-initiated Class II recall (D-0159-2025) for specific lots of its Chlorpromazine Hydrochloride Tablets, USP, 10mg. The recall, initiated on December 11, 2024, and reported on January 1, 2025, stems from critical Current Good Manufacturing Practice (CGMP) deviations. Specifically, the product was found to contain N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) at levels exceeding the current FDA recommended limits. This finding is particularly concerning for senior decision-makers, as nitrosamine impurities are classified as probable human carcinogens, necessitating stringent control and detection throughout the pharmaceutical manufacturing process. The affected product, identified by application number ANDA212144 and various NDCs including 68462-861-01, was distributed nationwide across the USA. For procurement directors, this incident underscores the imperative for enhanced supplier qualification and robust analytical testing protocols for all incoming active pharmaceutical ingredients (APIs) and finished drug products. The presence of such impurities directly impacts product safety and regulatory compliance, potentially leading to significant market disruptions and reputational damage. Regulatory affairs heads must ensure their internal quality systems are aligned with evolving FDA guidance on nitrosamine detection and control to mitigate similar risks.
Manufacturing Origin and Quality Control Implications for Chlorpromazine HCl Supply
While Glenmark Pharmaceuticals Inc., USA, located at 750 Corporate Dr, Mahwah, NJ 07430-2009, is the recalling firm, the product description explicitly states "Product of India." This detail is crucial for supply chain VPs and business development executives. It indicates that the CGMP deviations leading to the NNDCI impurity likely originated at the manufacturing site in India, highlighting the complexities and inherent risks associated with global pharmaceutical supply chains. The affected lots, 17230132 (Exp 12/2024) and 17230449 (Exp 01/2025), represent a total of 3,888 bottles of the 10mg, 100-count Chlorpromazine Hydrochloride tablets. This event necessitates a rigorous re-evaluation of quality agreements and oversight mechanisms for offshore manufacturing partners. Companies relying on imported APIs or finished products must implement comprehensive audit programs and robust vendor management systems to ensure adherence to FDA's CGMP standards, regardless of geographic location. Failure to do so can result in costly recalls, market withdrawals, and potential import alerts, directly impacting market access and revenue streams for products like Chlorpromazine Hydrochloride, a critical medication.
Supply Chain Exposure: Impact on Downstream Formulators and Market Availability
The nationwide distribution of Glenmark's Chlorpromazine Hydrochloride Tablets means that this Class II recall has broad implications for the US pharmaceutical market. While the recalled quantity of 3,888 bottles may not represent a massive market share, the underlying issue of nitrosamine contamination due to CGMP deviations is a significant concern for all stakeholders. Procurement directors must immediately assess their inventory of Glenmark's Chlorpromazine Hydrochloride and identify any affected lots to prevent further distribution. More broadly, this incident serves as a stark reminder for downstream formulators and distributors to scrutinize the quality control processes of all their suppliers, especially for generic medications where cost pressures can sometimes lead to overlooked quality risks. The potential for supply disruptions, even for a single product, can have cascading effects on patient access and healthcare providers. Business development executives should monitor such recalls closely, as they can signal opportunities for alternative suppliers with robust quality systems to gain market share, particularly in the psychotropic drug segment where Chlorpromazine Hydrochloride plays a role in treating conditions like schizophrenia.
Strategic Sourcing: Navigating Nitrosamine Risk in API Procurement
Given the absence of specific alternative suppliers in the current intelligence, procurement teams must proactively identify and qualify new sources for Chlorpromazine Hydrochloride API, or finished drug product, that can demonstrate rigorous control over nitrosamine impurities. The qualification process must extend beyond standard analytical testing to include comprehensive audits of manufacturing processes, raw material sourcing, and solvent quality, as nitrosamines can form through various pathways. Companies should prioritize suppliers with a proven track record of FDA compliance and transparent quality management systems. Geographic diversity in sourcing is also a critical consideration to mitigate single-point-of-failure risks, especially for products manufactured in regions with varying regulatory oversight. Qualification timelines for new API suppliers can range from 12 to 24 months, depending on the complexity of the molecule and the regulatory requirements, making proactive identification essential. Regulatory affairs heads must be prepared to support the necessary regulatory filings and amendments for changes in API source, ensuring a seamless transition and continuous supply of Chlorpromazine Hydrochloride without compromising patient safety or compliance.
Regulatory Scrutiny and Compliance Trajectory for Nitrosamine Contamination
This Class II recall by Glenmark Pharmaceuticals Inc., USA, for Chlorpromazine Hydrochloride Tablets underscores the FDA's heightened and ongoing scrutiny of nitrosamine impurities in pharmaceutical products. While the provided intelligence does not detail prior specific regulatory actions against Glenmark, any CGMP deviation leading to a recall, particularly involving a probable carcinogen like NNDCI, can escalate regulatory oversight. Regulatory affairs heads should anticipate increased scrutiny during future FDA inspections, not only for Glenmark but potentially for other manufacturers of similar drug products. The FDA expects firms to conduct thorough root cause analyses, implement comprehensive Corrective and Preventive Actions (CAPAs), and demonstrate sustained control over impurity levels. Failure to adequately address these issues can lead to more severe regulatory actions, including Warning Letters, import alerts for manufacturing facilities, and ultimately, market withdrawal of products. This incident serves as a critical reminder that proactive investment in quality systems and continuous monitoring of regulatory landscapes are non-negotiable for maintaining market access and ensuring long-term business continuity in the global chemical and life sciences industry.
Remediation Pathways and Future Market Outlook for Glenmark and Chlorpromazine HCl
Glenmark Pharmaceuticals Inc., USA, is now obligated to conduct a thorough investigation into the root cause of the N-Nitroso-Desmethyl Chlorpromazine impurity and implement robust corrective actions. This includes evaluating all manufacturing processes, raw material specifications, and testing methodologies for Chlorpromazine Hydrochloride. The ongoing status of the recall (D-0159-2025) indicates that the firm is actively managing the situation, but the long-term implications for its market standing and future product approvals remain significant. For business development executives, this event highlights the importance of supplier resilience and the ability to pivot to alternative sources quickly. The market for Chlorpromazine Hydrochloride, a long-established antipsychotic, is mature, but any supply disruption can create immediate demand for competitors. Regulatory affairs teams must prepare for potential reinspections by the FDA, where the effectiveness of Glenmark's CAPA plan will be rigorously assessed. The industry's collective experience with nitrosamine contamination in other drug classes, such as sartans and ranitidine, demonstrates that regulatory expectations will only intensify, requiring continuous investment in analytical capabilities and quality assurance to prevent similar occurrences and maintain consumer trust.